New San Diego Biotech K2 Therapeutics Locks In Over $30 Million, Company Name To Change Soon
6/26/2014 6:42:47 AM
A new San Diego biotech, led by former Trius Therapeutics CEO Jeff Stein, has raised over $30 million to advance new drugs to treat life-threatening invasive fungal infections, according to a recent regulatory filing.
Stein declined to discuss the financing by phone this morning, saying a press release is planned next week for the seed-stage startup, which is undergoing a name change. The San Diego startup apparently aims to develop compounds that elicit or amplify an immune response to fungal infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by